Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Realistically, there’s a good chance your patients are using them to get GLP-1 agonists. And sometimes Ro’s practice will resort to using compounding pharmacies too, only if all other options ...

One in eight. That's how many people living in the United States have taken some form of a glucagon-like peptide 1, otherwise known as a GLP-1, medication for weight loss and related conditions ...

They found that while bleeding and infection occurred about as often whether or not the patients were taking GLP-1 drugs, hematoma and wound re-opening occurred markedly less often- patients on ...

In a meta-analysis of nine randomized controlled trials, adults had an average lean mass loss of 2.5 kg with GLP-1 therapy. More research is needed to examine the implications of lean mass loss ...

Glucagon-like peptide-1 (GLP-1) is a fullness hormone that helps the body regulate blood sugar, appetite and metabolism. Ozempic, Mounjaro, Wegovy and similar drugs are GLP-1 receptor agonists ...

The uptake of GLP-1 has surged since 2022, mainly in US. Read our takeaways from the UBS Evidence Lab survey on key trends in GLP-1 consumer behaviour GLP-1s, also known as glucagon-like peptide 1, ...

Consumers taking GLP-1 drugs like Ozempic will need to adapt their shopping habits and diets, opening opportunities for food and drink makers to cash in. Consumers taking GLP-1 drugs to lose weight ...

Nationwide research reassures the short-term psychiatric safety of GLP-1 RAs, with no heightened risk observed in patients with psychiatric disorders or obesity. Study: Suicide and suicide attempt ...